- AbbVie (NYSE:ABBV) resumed with Buy rating and $103 (8% upside) price target by BofAML.
- Acorda Therapeutics (NASDAQ:ACOR) resumed with Neutral rating and $22 (10% upside) price target by Piper Jaffray.
- Bristol-Myers Squibb (NYSE:BMY) resumed with Neutral rating and $63 (2% upside) price target by BofAML.
- Henry Schein (NASDAQ:HSIC) initiated with Equal Weight rating and $76 (9% upside) price target by Stephens.
- Jazz Pharmaceuticals (NASDAQ:JAZZ) resumed with Buy rating and $164 (19% upside) price target by BofAML.
- Eli Lilly (NYSE:LLY) resumed with Neutral rating and $84 (flat) price target by BofAML.
- Loxo Oncology (NASDAQ:LOXO) initiated with Outperform rating by William Blair.
- Mallinckrodt (NYSE:MNK) resumed with Underperform rating and $20 (8% downside risk) price target by BofAML.
- Merck (NYSE:MRK) resumed with Buy rating and $64 (17% upside) price target by BofAML.
- Mylan N.V. (NASDAQ:MYL) resumed with Neutral rating and $39 (7% upside) price target by BofAML.
- Pfizer (NYSE:PFE) resumed with Buy rating and $40 (13% upside) price target by BofAML.
- Synlogic (NASDAQ:SYBX) initiated with Outperform rating and $20 (97% upside) price target by Wedbush.
- Teva Pharmaceutical Industries (NYSE:TEVA) resumed with Underperform rating and $11 (25% downside risk) price target by BofAML.
- Voyager Therapeutics (NASDAQ:VYGR) resumed with Overweight rating and $28 (110% upside) price target by Piper Jaffray.
- DENTSPLY SIRONA (NASDAQ:XRAY) initiated with Overweight rating and $75 (10% upside) price target by Stephens.
- Source: Bloomberg
- Now read: Henry Schein Now Inexpensive After 20% Drop
Original article